Welcome to our dedicated page for Hemogenyx Pharma news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharma stock.
Hemogenyx Pharmaceuticals plc develops clinical-stage biopharmaceutical therapies for blood and autoimmune diseases. Company news centers on HG-CT-1, its CAR-T cell therapy program for relapsed or refractory acute myeloid leukemia, including FDA IND reporting, clinical development updates, product stability work and lentiviral-vector manufacturing processes.
Recurring announcements also cover the company's CDX and CBR product candidates, platform technologies used for novel product development, and capital-market actions such as equity issuance, warrant exercises, prospectus publication, total voting rights and admissions of ordinary shares to trading on the London Stock Exchange.
Hemogenyx Pharmaceuticals plc (OTC PINK:HOPHF) announced on March 31, 2021, that its total issued share capital comprises 454,509,503 ordinary shares of 1 pence each, with none held in treasury. This total establishes the number of voting rights available to shareholders, which they may use as a denominator for notifications regarding changes in their investment under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The company emphasizes that all shares are fully issued and voting rights are in effect.
Hemogenyx Pharmaceuticals announced the allotment of 1,000,000 new ordinary shares (£0.01 each) for financial consulting services to Prosdocimi Limited. These shares will be admitted to trading on or around April 6, 2021. Following this admission, the total number of ordinary shares will be 469,795,217, which shareholders can use to assess their interest in the company's share capital under the Financial Conduct Authority's regulations.